Aptevo Therapeutics Inc
NASDAQ:APVO
Income Statement
Earnings Waterfall
Aptevo Therapeutics Inc
Revenue
|
0
USD
|
Operating Expenses
|
-28.9m
USD
|
Operating Income
|
-28.9m
USD
|
Other Expenses
|
11.5m
USD
|
Net Income
|
-17.4m
USD
|
Income Statement
Aptevo Therapeutics Inc
Dec-2015 | Mar-2016 | Jun-2016 | Sep-2016 | Dec-2016 | Mar-2017 | Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||||||||||||||||||||||||||
Revenue |
34
N/A
|
30
-11%
|
19
-36%
|
16
-19%
|
10
-36%
|
4
-59%
|
11
+178%
|
15
+30%
|
15
+0%
|
17
+13%
|
20
+20%
|
20
-2%
|
23
+18%
|
19
-18%
|
12
-36%
|
6
-48%
|
0
N/A
|
0
N/A
|
0
N/A
|
2
+311%
|
4
+123%
|
7
+56%
|
9
+39%
|
11
+18%
|
12
+12%
|
13
+6%
|
10
-24%
|
7
-31%
|
3
-54%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
Gross Profit | ||||||||||||||||||||||||||||||||||
Cost of Revenue |
(17)
|
(17)
|
(12)
|
(13)
|
(12)
|
(7)
|
(10)
|
(8)
|
(5)
|
(9)
|
(8)
|
(9)
|
(11)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Gross Profit |
17
N/A
|
13
-20%
|
7
-46%
|
3
-60%
|
(2)
N/A
|
(3)
-27%
|
1
N/A
|
6
+665%
|
10
+50%
|
8
-16%
|
12
+46%
|
11
-8%
|
12
+9%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
Operating Income | ||||||||||||||||||||||||||||||||||
Operating Expenses |
(78)
|
(76)
|
(70)
|
(72)
|
(65)
|
(135)
|
(135)
|
(60)
|
(64)
|
(63)
|
(65)
|
(66)
|
(64)
|
(68)
|
(59)
|
(53)
|
(41)
|
(37)
|
(36)
|
(31)
|
(32)
|
(33)
|
(35)
|
(35)
|
(34)
|
(33)
|
(32)
|
(32)
|
(32)
|
6
|
(31)
|
(30)
|
(29)
|
|
Selling, General & Administrative |
(43)
|
(43)
|
(39)
|
(42)
|
(36)
|
(37)
|
(38)
|
(34)
|
(35)
|
(32)
|
(31)
|
(30)
|
(28)
|
(25)
|
(22)
|
(19)
|
(16)
|
(15)
|
(14)
|
(13)
|
(14)
|
(14)
|
(16)
|
(16)
|
(15)
|
(15)
|
(14)
|
(14)
|
(14)
|
(14)
|
(13)
|
(12)
|
(12)
|
|
Research & Development |
(35)
|
(34)
|
(31)
|
(30)
|
(29)
|
(27)
|
(26)
|
(26)
|
(29)
|
(31)
|
(34)
|
(36)
|
(35)
|
(34)
|
(30)
|
(29)
|
(25)
|
(22)
|
(20)
|
(17)
|
(18)
|
(19)
|
(19)
|
(19)
|
(19)
|
(19)
|
(18)
|
(18)
|
(18)
|
(17)
|
(19)
|
(18)
|
(17)
|
|
Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
(71)
|
(71)
|
0
|
0
|
0
|
0
|
0
|
0
|
(9)
|
(7)
|
(4)
|
0
|
0
|
(2)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
37
|
0
|
0
|
0
|
|
Operating Income |
(61)
N/A
|
(63)
-3%
|
(63)
0%
|
(69)
-10%
|
(68)
+2%
|
(138)
-104%
|
(134)
+3%
|
(54)
+60%
|
(54)
+0%
|
(55)
-3%
|
(53)
+4%
|
(55)
-3%
|
(52)
+6%
|
(49)
+5%
|
(47)
+4%
|
(47)
+1%
|
(41)
+12%
|
(37)
+9%
|
(36)
+4%
|
(29)
+20%
|
(28)
+4%
|
(27)
+3%
|
(26)
+4%
|
(24)
+6%
|
(21)
+11%
|
(20)
+6%
|
(22)
-9%
|
(25)
-14%
|
(29)
-15%
|
6
N/A
|
(31)
N/A
|
(30)
+4%
|
(29)
+4%
|
|
Pre-Tax Income | ||||||||||||||||||||||||||||||||||
Interest Income Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Non-Reccuring Items |
0
|
0
|
0
|
(71)
|
(71)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(2)
|
0
|
(2)
|
(2)
|
0
|
0
|
0
|
0
|
0
|
37
|
37
|
37
|
0
|
0
|
0
|
0
|
|
Gain/Loss on Disposition of Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
10
|
10
|
10
|
10
|
|
Total Other Income |
(0)
|
0
|
0
|
(0)
|
(1)
|
(1)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(1)
|
(1)
|
(1)
|
(2)
|
(4)
|
(6)
|
(8)
|
(9)
|
(9)
|
(7)
|
(2)
|
1
|
3
|
3
|
1
|
|
Pre-Tax Income |
(61)
N/A
|
(63)
-2%
|
(63)
0%
|
(141)
-124%
|
(140)
+1%
|
(139)
+0%
|
(136)
+2%
|
(56)
+59%
|
(56)
0%
|
(57)
-2%
|
(55)
+4%
|
(57)
-3%
|
(54)
+6%
|
(51)
+4%
|
(49)
+4%
|
(49)
+1%
|
(43)
+12%
|
(41)
+4%
|
(37)
+10%
|
(32)
+14%
|
(31)
+4%
|
(29)
+8%
|
(30)
-4%
|
(30)
0%
|
(29)
+2%
|
(30)
-1%
|
6
N/A
|
6
-12%
|
7
+26%
|
17
+139%
|
(19)
N/A
|
(18)
+8%
|
(19)
-6%
|
|
Net Income | ||||||||||||||||||||||||||||||||||
Tax Provision |
2
|
2
|
2
|
19
|
20
|
21
|
21
|
17
|
23
|
0
|
0
|
8
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
(1)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Income from Continuing Operations |
(59)
|
(61)
|
(61)
|
(122)
|
(120)
|
(119)
|
(115)
|
(39)
|
(33)
|
(35)
|
(34)
|
(49)
|
(54)
|
(51)
|
(49)
|
(48)
|
(43)
|
(41)
|
(37)
|
(33)
|
(31)
|
(29)
|
(30)
|
(30)
|
(29)
|
(30)
|
6
|
6
|
7
|
17
|
(19)
|
(18)
|
(19)
|
|
Net Income (Common) |
(59)
N/A
|
(61)
-3%
|
(56)
+8%
|
(115)
-105%
|
(112)
+3%
|
(109)
+3%
|
(108)
+2%
|
2
N/A
|
7
+292%
|
3
-56%
|
1
-64%
|
(49)
N/A
|
(54)
-9%
|
(52)
+3%
|
(52)
0%
|
(46)
+11%
|
(40)
+13%
|
(26)
+37%
|
(19)
+26%
|
(19)
+1%
|
(18)
+6%
|
(28)
-57%
|
(29)
-4%
|
(29)
-1%
|
(28)
+3%
|
(29)
-2%
|
7
N/A
|
6
-9%
|
8
+25%
|
19
+130%
|
(17)
N/A
|
(16)
+8%
|
(17)
-8%
|
|
EPS (Diluted) |
-41.19
N/A
|
-42.49
-3%
|
-38.56
+9%
|
-79.56
-106%
|
-77.53
+3%
|
-73.97
+5%
|
-70.94
+4%
|
1.14
N/A
|
4.58
+302%
|
1.95
-57%
|
0.66
-66%
|
-30.44
N/A
|
-33.34
-10%
|
-33.03
+1%
|
-16.16
+51%
|
-14.36
+11%
|
-13.85
+4%
|
-7.8
+44%
|
-5.87
+25%
|
-5.83
+1%
|
-5.23
+10%
|
-6.31
-21%
|
-6.39
-1%
|
-5.97
+7%
|
-6.06
-2%
|
-5.85
+3%
|
1.4
N/A
|
1.25
-11%
|
1.57
+26%
|
2.63
+68%
|
-2.69
N/A
|
0
N/A
|
-62.61
N/A
|